X
MRNA icon

Xponance’s Moderna MRNA Stock Holding History

Xponance’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Buy
39,368
+817
+2% +$42.3K 0.02% 524
2026
Q1 		$1.96M Buy
38,551
+8,209
+27% +$383K 0.01% 576
2025
Q4 		$895K Buy
30,342
+2,975
+11% +$80.8K 0.01% 725
2025
Q3 		$707K Sell
27,367
-3,530
-11% -$98.5K 0.01% 832
2025
Q2 		$852K Sell
30,897
-14,515
-32% -$382K 0.01% 751
2025
Q1 		$1.29M Buy
45,412
+642
+1% +$22.8K 0.01% 613
2024
Q4 		$1.86M Sell
44,770
-414
-0.9% -$19.8K 0.02% 544
2024
Q3 		$3.02M Buy
45,184
+1,112
+3% +$102K 0.03% 426
2024
Q2 		$5.23M Sell
44,072
-387
-0.9% -$49K 0.05% 272
2024
Q1 		$4.74M Buy
44,459
+2,050
+5% +$207K 0.05% 311
2023
Q4 		$4.22M Buy
42,409
+2,489
+6% +$209K 0.05% 303
2023
Q3 		$4.12M Buy
39,920
+910
+2% +$102K 0.06% 283
2023
Q2 		$4.74M Sell
39,010
-3,629
-9% -$484K 0.06% 262
2023
Q1 		$6.55M Sell
42,639
-2,753
-6% -$454K 0.1% 192
2022
Q4 		$8.15M Buy
45,392
+5,479
+14% +$896K 0.13% 148
2022
Q3 		$4.72M Buy
39,913
+9,307
+30% +$1.41M 0.09% 199
2022
Q2 		$4.37M Sell
30,606
-27,604
-47% -$3.95M 0.09% 192
2022
Q1 		$10M Sell
58,210
-2,998
-5% -$505K 0.17% 103
2021
Q4 		$15.5M Buy
61,208
+4,984
+9% +$1.46M 0.24% 73
2021
Q3 		$21.6M Buy
56,224
+16,646
+42% +$6.14M 0.41% 38
2021
Q2 		$9.3M Buy
39,578
+9,543
+32% +$1.71M 0.17% 104
2021
Q1 		$3.93M Buy
30,035
+441
+1% +$63.9K 0.08% 199
2020
Q4 		$3.09M Sell
29,594
-155
-0.5% -$15.7K 0.07% 238
2020
Q3 		$2.1M Buy
29,749
+1,797
+6% +$125K 0.05% 278
2020
Q2 		$1.79M Buy
+27,952
New +$1.53M 0.05% 282

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Xponance's MRNA Position: Q2 2026 in Review

Xponance increased its Moderna (MRNA) stake by 2.1% in Q2 2026, buying an estimated $42.3K and bringing the position to 39,368 shares worth $2.76M. The position accounts for 0.02% of the portfolio, ranked #524.

Xponance first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $21.6M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Xponance held 39,368 shares of Moderna worth $2.76M as of Q2 2026.
  • Xponance bought 817 Moderna shares in Q2 2026, an estimated $42.3K.
  • Moderna made up 0.02% of Xponance's portfolio in Q2 2026, its #524 holding.
  • Xponance first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Moderna position peaked at $21.6M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.